Estudo de fase 3 de concentrado de inibidor de esterase C1 derivado de plasma humano IV em pacientes com deficiência congênita de C1-INH para tratamento e prevenção pré-procedimento de ataques agudos de angioedema hereditário
Estudo prospectivo, multicêntrico, randomizado, duplo-cego, grupo paralelo, controlado por placebo, eficácia e segurança de fase 3 de um concentrado intravenoso de inibidor de esterase C1 derivado de plasma humano (C1-INH) em participantes com deficiência congênita de C1-INH para o tratamento e prevenção pré-procedimento de ataques agudos de angioedema hereditário
Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Theresa Conklin
- Número de telefone: 8663371868
- E-mail: ctgov@clinicalresearchmgt.com
Locais de estudo
-
-
-
Tirana, Albânia
- Retirado
- Octapharma Research Site
-
-
-
-
-
Rosario, Argentina
- Recrutamento
- Octapharma Research Site
-
-
-
-
-
Yerevan, Armênia
- Recrutamento
- Octapharma Research Site
-
-
-
-
-
Sofia, Bulgária, 1431
- Recrutamento
- Octapharma Research Site
-
-
-
-
Colorado
-
Centennial, Colorado, Estados Unidos, 80112
- Retirado
- Octapharma Research Site
-
-
Michigan
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Retirado
- Octapharma Research Site
-
-
Ohio
-
Toledo, Ohio, Estados Unidos, 43617
- Retirado
- Octapharma Research Site
-
-
-
-
-
Podgorica, Montenegro
- Retirado
- Octapharma Research Site
-
-
-
-
-
Mexico City, México, 06720
- Ainda não está recrutando
- Octapharma Research Site
-
México, México
- Ainda não está recrutando
- Octapharma Research Site
-
-
-
-
-
Lima, Peru, 15001
- Recrutamento
- Octapharma Research Site 5103
-
Lima, Peru, 15001
- Recrutamento
- Octapharma Research Site 5102
-
-
-
-
-
Cluj-Napoca, Romênia, 400162
- Retirado
- Octapharma Research Site
-
-
-
-
-
Kragujevac, Sérvia, 11221
- Retirado
- Octapharma Research Site
-
-
-
-
-
Ankara, Turquia (Türkiye)
- Ainda não está recrutando
- Octapharma Research Site
-
Istanbul, Turquia (Türkiye)
- Ainda não está recrutando
- Octapharma Research Site
-
Izmir, Turquia (Türkiye)
- Retirado
- Octapharma Research Site
-
Sakarya, Turquia (Türkiye)
- Ainda não está recrutando
- Octapharma Research Site
-
-
-
-
-
Kyiv, Ucrânia, 03057
- Recrutamento
- Octapharma Research Site
-
Lviv, Ucrânia, 79035
- Ainda não está recrutando
- Octapharma Research Site
-
Lviv, Ucrânia, 79010
- Retirado
- Octapharma Research Site
-
-
-
-
-
Bangalore, Índia, 560017
- Ainda não está recrutando
- Octapharma Research Site
-
Chhatrapati Sambhajinagar, Índia, 431003
- Ainda não está recrutando
- Octapharma Research Site, Chhatrapati Sambhajinagar
-
Hyderabad, Índia, 500003
- Ainda não está recrutando
- Octapharma Research Site
-
Patna, Índia, 801507
- Ainda não está recrutando
- Octapharma Research Site
-
Srinagar, Índia, 190010
- Ainda não está recrutando
- Octapharma Research Site
-
-
Maharashtra
-
Pune, Maharashtra, Índia, 411040
- Ainda não está recrutando
- Octapharma Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Is at least 18 years of age (applicable for 1st study phase) or is at least 2 years of age (applicable for 2nd study phase)
-
Has confirmed diagnosis of HAE type I or II
-
Has had at least 3 moderate or severe HAE attacks (excluding extremity attacks) in the last 3 months before the Screening Visit. For participants ≥2 and ≤12 years of age, has had at least 1 moderate or severe HAE attack (excluding extremity attacks) in the last 6 months before Screening Visit
-
Has a documented congenital C1-INH functional activity <50% with or without C1-INH deficiency and C4 antigen level below the laboratory reference range
-
Participant or the participant's legally authorized representative(s) has signed informed consent (as required by local law), with the assent of participants legally capable of providing it, as applicable
-
States willingness to comply with all study procedures and availability for the duration of the study
-
If the participant is of childbearing potential (CBP), has a negative pregnancy test and must have been using a highly effective method of contraception and continue to do so until at least 2 weeks after their last dose (for both blinded and open-label doses of IMP). Not of CBP is defined as surgically sterilized (hysterectomy, bilateral oophorectomy) or who are postmenopausal (defined as women with no menses for 12 months without an alternative medical cause). Highly effective methods of contraception:
- Combined hormonal contraception (estrogens and progesterone) methods such as oral, implantable, intravaginal, injectable, or transdermal contraceptives at a stable dose for a minimum of 1 full cycle (hormonal contraceptives must inhibit ovulation) and for at least 4 weeks before screening
- Progesterone only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- Intrauterine device
- Intrauterine hormone-releasing system inserted at least 4 weeks before screening
- Bilateral tubal ligation/occlusion or vasectomized partner (with surgical success confirmed by medical assessment) OR Agrees to abstain from heterosexual intercourse during study participation and to use a highly effective contraceptive (as described above) as backup if they become sexually active during the study. Abstinence is only acceptable if this is the participant's usual lifestyle. Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception
- Note: If a participant of CBP has a positive or suspected positive urine pregnancy test within 72 hours prior to treatment, a serum pregnancy test will be required
- Male participants must not plan to father a child or donate sperm for 90 days after their last dose of study drug (for both blinded and open-label doses of the IMP). However, there are no official contraception requirements for male participants during the study.
Inclusion Criteria for IMP Dosing for QAT:
- Has confirmed QAT per definition criteria
- Has a swelling episode that is new and not the continuation of a previous HAE attack
Exclusion Criteria:
- Has a history of clinically relevant antibody development against C1-INH
- Has a medical history consistent with Type 3 HAE (i.e., onset at age above 40 year, no family history, no known HAE mutation, low C1q level in plasma)
- Has a history of allergic reaction to C1-INH or other blood/plasma product
- Has a history of B-cell malignancy that was unresolved in the past 5 years
- Has a narcotic and/or alcoholic addiction
- Has participated in any other investigational drug evaluation within 30 days before screening
- Is pregnant or breastfeeding
- Has any clinically significant medical or psychiatric condition that, in the investigator's opinion would interfere with the participant's ability to participate in the study
- Has a history of thromboembolic events (TEEs), myocardial infarction, unstable angina pectoris, critical aortic stenosis, cerebrovascular accident, transient ischemic attack, severe peripheral vascular disease, or disseminated intravascular coagulation within one year before screening
- (applicable until IDMC review of the interim preliminary safety and efficacy data): has clinically significant derangement in measurements of cardiovascular status (i.e. uncontrolled arterial hypertension, cardiac insufficiency New York Heart Association (NYHA) class III-IV), pulmonary status (i.e., COPD GOLD classification 3 and 4, severe asthma) and renal status (i.e., eGFR below 90 ml/min per 1.73 m2)
Exclusion Criteria for IMP Dosing for QAT:
- Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
- started or changed hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) within 14 days before IMP dosing
- Started or changed androgen therapy (e.g. testosterone, dehydro- epiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) within 14 days before IMP dosing or is not willing to maintain a stable dose throughout the study
- Started or changed the dose of monoclonal antibodies e.g. lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
- Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing for a QAT
- Has received OCTA-C1-INH within 14 days before IMP dosing
Exclusion Criteria for IMP Dosing for PK:
- Has received blood or a blood product for prophylactic or acute treatment with any C1-INH (Berinert®, Cinryze®, HAEgarda®, Ruconest®, etc.), non-biological bradykinin and kallikrein pathway inhibitors (e.g., ecallantide, icatibant, berotralstat), or treatment with tranexamic acid within 14 days before dosing with the IMP (or is not willing to abstain from these medications throughout the study)
- Is receiving hormone replacement therapy or selective estrogen receptor modulators (e.g., tamoxifen) and has had their dose changed within 14 days before IMP dosing
- Is receiving or has received androgen therapy (e.g., testosterone, dehydroepiandrosterone/androstenedione, oxandrolone, danazol, stanozolol) IN ANY DOSE within 14 days before dosing
- Started or changed the dose of monoclonal antibodies e.g lanadelumab within 11 weeks before dosing or not willing to maintain a stable dose throughout the study
- Has used narcotic pain medications or non-opioid analgesics within 7 days before IMP dosing
- Has received IMP within 14 days before IMP dosing
- Has planned dental, medical, or surgical procedures during the PK Period that will require pre-procedural prevention
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: OCTA-C1-INH
OCTA-C1-INH injection, 20IU/kg BW after first qualifying attack. Treatment to be administered to blinded as well as open-label subjects. |
OCTA-C1-INH is a stable, sterile, virus-inactivated, nano-filtered, highly purified concentrate of human C1-INH prepared from pooled human plasma. After reconstitution in 2.5mL water for injection, the solution can be administered as a slow IV injection. OCTA-C1-INH is given as a dose of 20 IU/kg body weight (BW) |
|
Comparador de Placebo: Placebo
0.1 mL/kg BW 0.9% sodium chloride solution injection after first qualifying attack. Only blinded subjects to receive. |
0.1 mL/kg BW 0.9% sodium chloride injection |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time (h) to beginning of unequivocal symptom relief at the defining site in blinded participants.
Prazo: Within 4 hours after injection
|
Patient will rate symptom relief for the defining attack site (site of swelling or pain) from 15 minutes after start of the IMP injection every 15 minutes over 4 hours. Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade SRRS. This measure will also be used for the secondary outcomes in a different context. |
Within 4 hours after injection
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Percentage of participants responding to treatment
Prazo: within 4 hours after injection
|
Percentage of patients responding to treatment, defined as beginning of unequivocal symptom relief at the defining site within 4 hours after injection (once per participant after first qualifying attack in the study). Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade symptom relief rating. |
within 4 hours after injection
|
|
Time to beginning of unequivocal symptom relief at all sites involved
Prazo: Within 4 hours after injection
|
Time to the beginning of unequivocal symptom relief at all sites involved within 4 hours after injection. Unequivocal relief is defined as having 3 consecutive reports of "absent now but present before," "absent now and absent before", or "present, symptoms better" on the 5-grade symptom relief rating. |
Within 4 hours after injection
|
|
Changes in symptom severity at the defining site by VAS severity rating
Prazo: Within 4 hours after injection
|
Changes in symptom severity at the defining site by visual analog scale (VAS) rating from pre-injection over 4 hours after injection. The VAS is a self-reported 0-100 pain and swelling rating scale. |
Within 4 hours after injection
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CONE-02
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .